EP Patent

EP4651860A1 — Crystalline nanoparticles comprising enzalutamide

Assigned to Helm Pharmaceuticals GmbH · Expires 2025-11-26 · 0y expired

What this patent protects

The invention relates to a composition comprising or essentially consisting of (i) nanoparticles comprising or essentially consisting of Enzalutamide in crystalline form and (ii) one or more physiologically acceptable polymers and/or copolymers. The invention also relates to proc…

USPTO Abstract

The invention relates to a composition comprising or essentially consisting of (i) nanoparticles comprising or essentially consisting of Enzalutamide in crystalline form and (ii) one or more physiologically acceptable polymers and/or copolymers. The invention also relates to processes for the preparation of such compositions, pharmaceutical dosage forms comprising or made from such compositions, and uses of such pharmaceutical dosage forms for medical purposes.

Drugs covered by this patent

Patent Metadata

Patent number
EP4651860A1
Jurisdiction
EP
Classification
—
Expires
2025-11-26
Drug substance claim
No
Drug product claim
No
Assignee
Helm Pharmaceuticals GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.